SEC Company Response from Coherus Oncology, Inc. (CHRS) (CIK 0001512762) (CHRS) — Feb 14, 2018
Coherus Oncology, Inc. (CHRS) (CIK 0001512762)
Date: Feb. 14, 2018 · CIK: 0001512762 · Accession: 0001193125-18-045572
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-222698
Letter
Coherus BioSciences, Inc.
333 Twin Dolphin Drive, Suite 600
Redwood City, CA 94065
February 14,
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
Attention: Chris Edwards
Re: Coherus BioSciences, Inc.
Registration Statement on Form S-3 (Registration No. 333-222698)
Ladies and Gentlemen:
In accordance with Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, we hereby request acceleration by the Securities and Exchange Commission of the effective date of the above-referenced Registration Statement on Form S-3 (the “Registration Statement”) of Coherus BioSciences, Inc. We respectfully request that the Registration Statement become effective as of 4:00 p.m., Washington, D.C. time, on February 19, 2018, or as soon as practicable thereafter.
Thank you for your assistance in this matter.
Very truly yours,
Coherus BioSciences, Inc.
Show Raw Text
CORRESP 1 filename1.htm CORRESP Coherus BioSciences, Inc. 333 Twin Dolphin Drive, Suite 600 Redwood City, CA 94065 February 14, 2018 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attention: Chris Edwards Re: Coherus BioSciences, Inc. Registration Statement on Form S-3 (Registration No. 333-222698) Ladies and Gentlemen: In accordance with Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, we hereby request acceleration by the Securities and Exchange Commission of the effective date of the above-referenced Registration Statement on Form S-3 (the “Registration Statement”) of Coherus BioSciences, Inc. We respectfully request that the Registration Statement become effective as of 4:00 p.m., Washington, D.C. time, on February 19, 2018, or as soon as practicable thereafter. Thank you for your assistance in this matter. Very truly yours, Coherus BioSciences, Inc. By: /s/ Jean-Frédéric Viret Jean-Frédéric Viret Chief Financial Officer